Literature DB >> 2479465

Depletion of T-cells with the CD4+CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma.

G Cardi1, M J Mastrangelo, D Berd.   

Abstract

We studied the phenotypes of lymphocytes extracted from 22 specimens of human melanoma, 11 s.c. metastases and 11 lymph node metastases, by two-color flow cytometry. Lymphocytes extracted from s.c. metastases were characterized by a significantly reduced ratio of CD4+ to CD8+ T-cells, as compared with peripheral blood lymphocytes from the same patients. Ten of 11 tumor-infiltrating lymphocytes from s.c. metastases, but only 1 of 11 peripheral blood lymphocytes, had a CD4/CD8 ratio of less than 1.0. This alteration was not observed for lymphocytes obtained from nodal metastases. Furthermore, almost all of the CD4+ T-cells in s.c. metastases expressed the antigen CD29w and were negative for the complementary antigen CD45R. In contrast, the CD29w/CD45R ratio of tumor-infiltrating lymphocytes from lymph node metastases was similar to that of matched peripheral blood lymphocytes. Thus tumor-infiltrating lymphocytes from s.c. metastases have the phenotype associated with true helper or antigen-committed T-cells, which could reflect their sensitization to tumor antigens, while tumor-infiltrating lymphocytes from lymph node metastases may represent merely an expanded residua of lymph node lymphocytes. Since tumor-infiltrating lymphocytes expanded in vitro are being tested as therapy for patients with advanced cancer, these observations may have important therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479465

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 2.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

3.  Oligoclonality of CD8+ T cells in breast cancer patients.

Authors:  K Ito; J Fetten; H Khalili; S Hajdu; E Busch; R Pergolizzi; V Vinciguerra; M D Chang
Journal:  Mol Med       Date:  1997-12       Impact factor: 6.354

4.  Expression of cytokine mRNA in human melanoma tissues.

Authors:  E C Lattime; M J Mastrangelo; O Bagasra; W Li; D Berd
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

5.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

6.  Oligoclonal expansion of V beta 8+ cells in interleukin-2-activated T cells residing in subcutaneous metastatic melanoma.

Authors:  T Morita; M A Salmeron; R P Moser; M I Ross; K Itoh
Journal:  Clin Exp Metastasis       Date:  1992-01       Impact factor: 5.150

7.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.

Authors:  L Ferradini; A Mackensen; C Genevée; J Bosq; P Duvillard; M F Avril; T Hercend
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine.

Authors:  D Berd; H C Maguire; M J Mastrangelo; G Murphy
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

9.  Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration.

Authors:  H Inoue; M Adachi; N Karimine; S Arinaga; H Ueo; D Korenaga; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 10.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.